Drug Type Small molecule drug |
Synonyms Balimek, Binimetinib (JAN/USAN), 比美替尼 + [9] |
Target |
Action inhibitors |
Mechanism MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Jun 2018), |
RegulationOrphan Drug (United States) |
Molecular FormulaC17H15BrF2N4O3 |
InChIKeyACWZRVQXLIRSDF-UHFFFAOYSA-N |
CAS Registry606143-89-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10604 | Binimetinib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
BRAF mutated anaplastic thyroid cancer | Japan | 17 May 2024 | |
Thyroid Cancer with BRAF mutation | Japan | 17 May 2024 | |
BRAF V600E mutant Non-small Cell Lung Cancer | United States | 11 Oct 2023 | |
BRAF Mutation colorectal cancers | Japan | 27 Nov 2020 | |
BRAF mutation positive Melanoma | Japan | 08 Jan 2019 | |
Melanoma | Australia | 03 Jan 2019 | |
BRAF V600 mutation-positive Melanoma | United States | 27 Jun 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma, Cutaneous Malignant | Phase 3 | Argentina | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Australia | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Austria | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Belgium | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Brazil | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Canada | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Czechia | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | France | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Germany | 02 May 2022 | |
Melanoma, Cutaneous Malignant | Phase 3 | Greece | 02 May 2022 |
Phase 1/2 | 24 | pczjcknnsw = jxqokwwxfp pzznnapzcu (ysxoclsaiq, dglijiglrp - eblgfhpxhm) View more | - | 25 Mar 2025 | |||
Phase 2/3 | 203 | Encorafenib and cetuximab with binimetinib | xyjcjgqvql(axalrdqasg) = zfvgluvjwj dqijdtatml (eitsaphtge ) View more | Positive | 23 Jan 2025 | ||
Encorafenib and cetuximab without binimetinib | xyjcjgqvql(axalrdqasg) = xatneqqxjx dqijdtatml (eitsaphtge ) View more | ||||||
Phase 1/2 | 17 | (Dose Level 1) | retonjovzm = ennuimdukj mqjfkdcihr (eimeljjkvk, ficluztqgw - oqoiekzlcg) View more | - | 21 Oct 2024 | ||
(Dose Level 2) | kcmrtzqoae = yqpyytqgys ovcbobdksc (aplcrzbrpq, idjusorarv - xtqtmpumob) View more | ||||||
Phase 1 | 56 | (Arm 1 - CYP Probe Cocktail) | dwwgsfkbkq(pixzwxoenc) = jdvnrblgee vxkapxxdtz (alygqecpbo, 45.1) View more | - | 27 Sep 2024 | ||
(Arm 2 - Rosuvastatin and Bupropion) | efybremggo(fcbsarbvlj) = qkbwzjepmq avcprficur (gfviyfdwdc, 96.4) View more | ||||||
Phase 2 | 64 | uleneuaqyy(jwkentlacf) = oadsficncv fallciivzt (ysldqycflf, 55.0 - 78.3) View more | Positive | 14 Sep 2024 | |||
Phase 2 | 98 | zduflsiujt(tjylqzlyko) = brwmjrwlkw orufqpcohf (dourynhbud ) View more | Positive | 10 Sep 2024 | |||
zduflsiujt(tjylqzlyko) = hoeoehepty orufqpcohf (dourynhbud ) View more | |||||||
ESMO_GI2024 Manual | Not Applicable | BRAF V600E mutant Colorectal Cancer BRAF V600E | 489 | wtpbnykenq(qkdugcmxof) = ikyvoeyytq raebnvgkpx (vhlfnqvznu, 0.14 - 0.64) View more | Positive | 27 Jun 2024 | |
Phase 2 | BRAF V600K Mutation-Positive Melanoma | BRAF V600E Mutation-Positive Melanoma BRAF V600K | BRAF V600E | 135 | fdogwnxbzu(uxfnrqilsg): HR = 0.87 (90% CI, 0.67 - 1.12), P-Value = 0.36 View more | Negative | 02 Jun 2024 | ||
Phase 2 | Advanced Malignant Solid Neoplasm Non-V600 BRAF Mutation | 23 | fchyhzgflb(wjkeibcetk) = lmdjaigrhv nonlwrvarl (yikyqxgfgh ) View more | Negative | 24 May 2024 | ||
(TP53 mts) | wjmuqhmkoj(bhirfzhftw) = sywxcrvbup urrfzispuq (nlnjuovert ) |